Olema Pharmaceuticals inc
OLMAHealthcare|Biotechnology|USA
$11.91
-0.38 (-3.09%)
Tangible Book
$5.50
Earnings Power
$4.80
Upcoming Data Readouts (3)
May 2027
Est. completion
P1Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193n=180
Dec 2027
Est. completion
P1Metastatic Breast Cancer
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906n=190
Dec 2028
Est. completion
P3Breast Cancer
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767n=1,000
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2026
P1
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
NCT05266105